Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials

Fig. 1

Difference between dual therapy vs. monotherapy in FEV1 change from baseline. CI confidence interval, FEV1 forced expiratory volume at 1 s, GOLD Global initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-2 agonist, LAMA long-acting muscarinic antagonist, LSM least squares mean

Back to article page